A cell-permeable, reversible 20S proteasome inhibitor with IC₅₀ values of 1 µM, 4.5 µM and 4.5 µM for CT-L, T-L and PGPH-L respectively. Exhibits CT-L (chymotrypsin-like) and cell proliferation inhibition selectively in ovarian, pancreatic, and breast cancer cells (T80-Hras, C7-Kras, and MCF-7, respectively) over their non-transformed counterparts (T80, C7, and MCF-10A), and induction of apoptosis with IC₅₀ values of 3.7 µM in an MTT assay on bone marrow cells isolated from multiple myeloma patients in vitro. Shown to have anti-tumor activities in a nude mouse xenograft model implanted with MCF-7 and A549 cells in vivo when dosed at 1 mpk, leading to significant tumor growth inhibition of 84%. PI-083 results in 43, 12 and 34% inhibition of tumor CT-L, T-L and PGPH activities respectively, compared to those of tumors from vehicle-treated controls, while it does not inhibit liver proteasome activities.，官网链接：https://www.sigmaaldrich.cn/product/mm/539187 默克 科研、开发、生产。 作为生命科学行业的全球领先供应商，我们致力于为科研、生物技术开发和生产，以及制药药物疗法开发和生产提供各类解决方案和服务。

非质量问题不退不换